Table 2: Main results for experimental studies.
Author, year |
Main result |
Systematic review conclusion |
Body weight |
||
Weight |
||
Rocha, et al. (2015) [33] |
No significant changes (p > 0.05) |
The intake of GT suggests a neutral or reduction effect on total body weight. |
Santana, et al. (2015) [34] |
Total body weight has decreased after GT treatment (p < 0.05) |
|
Lu, et al. (2012) [35] |
Total body weight has decreased after GT treatment (p < 0.05) |
|
Shen, et al. (2015) [36] |
No significant changes (p > 0.05) |
|
Body Fat Mass |
||
Shen, et al. (2015) [36] |
Body fat mass has decreased after GT treatment (p < 0.05) |
The intake of GT may suggest a neutral or reduction effect on body fat mass. |
Rocha, et al. (2015) [33] |
No significant changes (p > 0.05) |
|
Santana, et al. (2015) [34] |
No significant changes (p > 0.05) |
|
Body Fat-Free Mass |
||
Shen, et al. (2015) [36] |
Body fat-free mass has increased after GT treatment (p < 0.05) |
The intake of GT may suggest a elevation effect on body fat-free mass. |
Inflammatory profile |
||
TNF |
||
Santana, et al. (2015) [34] |
WAT TNF has decreased after GT treatment (p < 0.05) |
The intake of GT may suggest a reduction effect on liver TNF and a neutral effect on blood TNF. |
Rocha, et al. (2015) [33] |
No significant changes in blood TNF (p > 0.05) |
|
IL-6 |
||
ROCHA, et al. (2015) [33] |
No significant changes (p > 0.05) |
The intake of GT suggests a neutral or reduction effect on IL-6. |
Lu, et al. (2012) [35] |
Serum IL-6 has decreased after GT treatment (p < 0.05) |
|
IL-1β |
||
ROCHA, et al. (2015) [33] |
No significant changes (p > 0.05) |
The intake of GT suggests a neutral or reduction effect on IL-1β. |
Lu, et al. (2012) [35] |
Serum IL-1β has decreased after GT treatment (p < 0.05) |
|
Glycemic profile |
||
Glucose |
||
ROCHA, et al. (2015) [33] |
No significant changes (p > 0.05) |
The intake of GT may suggest a neutral or elevation effect on serum glucose. |
Santana, et al. (2015) [34] |
Serum glucose has increased after GT treatment (p < 0.05) |
|
Insulin |
||
Santana, et al. (2015) [34] |
Serum insulin has increased after GT treatment (p < 0.05) |
The intake of GT may suggest a elevation effect on serum insulin. |
Homa-IR |
||
Santana, et al. (2015) [34] |
HOMA-IR has increased after GT treatment (p < 0.05) |
The intake of GT may suggest a elevation effect on HOMA-IR. |
Cardiovascular health |
||
TC |
||
Rocha, et al. (2015) [33] |
No significant changes (p > 0.05) |
The intake of GT suggests a neutral effect on TC. |
Santana, et al. (2015) [34] |
No significant changes (p > 0.05) |
|
TG |
||
Rocha, et al. (2015) [33] |
No significant changes (p > 0.05) |
The intake of GT suggests a neutral effect on TG. |
Santana, et al. (2015) [34] |
No significant changes (p > 0.05) |
|
HDL |
||
Rocha, et al. (2015) [33] |
No significant changes (p > 0.05) |
The intake of GT suggests a neutral effect on HDL. |
Santana, et al. (2015) [34] |
No significant changes (p > 0.05) |
|
LDL |
||
Rocha, et al. (2015) [33] |
No significant changes (p > 0.05) |
The intake of GT suggests a neutral effect on LDL. |
Santana, et al. (2015) [34] |
No significant changes (p > 0.05) |
|
FFA |
||
Rocha, et al. (2015) [33] |
FFA has decreased after GT treatment (p < 0.05) |
The intake of GT suggests a neutral or reduction effect on FFA. |
Santana, et al. (2015) [34] |
No significant changes (p > 0.05) |
|
GT: Green Tea; WAT: White Adipose Tissue; TNF: Tumor Necrosis Factor; IL-6: Interleukin 6; IL-1β: Interleukin 1 beta; CRP: C-reactive Protein; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance; HbA1c: Glycated Hemoglobin; TC: Total Cholesterol; TG: Triglycerides; HDL: High-Density Lipoprotein Cholesterol; LDL: Low-Density Lipoprotein Cholesterol; FFA: Free Fatty Acids |